Life Sciences Archive » January, 2021

Life Sciences - January, 2021

348 articles

• Full Fed. Circ. Told State Universities Immune From IPR
• Drugmakers Must Face Fraud Claims In Valsartan MDL
• NJ Justices Won't Second-Guess Revival Of J&J Talc Cases
• Fowler White Avoids DQ, But Clients Sanctioned Over Emails
• AstraZeneca Hit With Investor Suit Over COVID-19 Vaccine
• Only Calif. Buyers Win Class Cert. In Joint Pill False Ad Suit
• 3 Firms Guide Biotech's $110M PIPE, Buy Of PE-Backed Co.
• Mass. Court Overturns Cost Ruling In Boston Drug Test Case
• Health Hires: Sidley Austin And King & Spalding
• EU Sets Temporary Export Controls On COVID-19 Vaccines
• Mass. High Court Tosses Suit Over Genzyme's Arthritis Device
• Partner Exits Firm Over Abuse Allegations Facing Colleague
• Nabriva Gets Initial Nod For $3M Investor Settlement
• UK Litigation Roundup: Here's What You Missed In London
• 4 Highlights As Biden Starts Scrubbing Trump's Health Legacy
• Feds Can't Dodge Gilead HIV Patent Counterclaims
• Mallinckrodt Seeks To Move Acthar Cases To Delaware
• Coronavirus Litigation: The Week In Review
• House Panel Probes $79M In Ventilator Deals For Abuse
• Novartis Must Face Ex-Lab Worker's Disability Bias Claims
• 9th Circ. Urged To Toss SmileDirect Harassment Suit
• ConEd Worker Fired For Medical Pot Use Can Sue, Court Says
• Real Estate Rumors: Vision Properties, Deutsche Bank, Stiles
• Watchdog 'Deeply Troubled' By Gaps In Feds' Vaccine Rollout
• Paul Weiss-Bound Orrick Attys Exit Theranos Case
• Deals Rumor Mill: Fenway Sports Group, KKR, 23andMe
• Feds Say Health Co. Used Masters, Derby Trips As Kickbacks
• Ex-Acclarent Execs Get $1.5M Fines Stayed Amid Appeal
• New Ariz. Law Practice Rules May Jump-Start National Reform
• US Merck Seeks To Upend Pfizer Pneumonia Vaccine Again
• Medical Device Co. Exec Gets 4 Months For Embezzling $1M
• 2 Firms Steer Materials Co.'s £403M Bet On UK Manufacturer
• Sanofi To Bottle Pfizer's Vaccine While It Works On Its Own
• Nevada Pot Testing Lab Doctored Results, Regulators Say
• Meet The Diverse Set Of Attorneys Leading The Elmiron MDL
• PTAB Weighs Novelty Of Bio-Rad DNA Microfluidics Techs
• Judge Polster Talks Senior Status And Opioid MDL's Future
• HHS Emergency Money Was Misappropriated, Watchdog Says
• States Urged Not To Use Opioid Mega-Deals For Budgets
• Real Estate Rumors: Kushner, Talis Biomedical, Ivy Realty
• Special Master Urges Toss Of Opt-Out Valeant Investor Suit
• 6 Firms Guide Advanz Pharma's $846M Nordic Capital Deal
• Pot Testing Co. Says Equipment Maker Sold Faulty Machines
• Nurse Says Fingers Can't Bend After Using Jewel Sanitizer
• NJ Court Lends Support To FDA Evidence In Mesh Cases
• Opioid MDL Judge Takes Senior Status, Setting Up Biden Pick
• ConMed Says Chubb Should Cover Chemical Exposure Claims
• Full Fed. Circ. Won't Take Up Hatch-Waxman Act Venue Limits
• Pot Sales Tracker Metrc Loses Mo. Fight To Collect Fees
• FDA Puts Mexican Sanitizers On Import Alert Over Toxin
• Eli Lilly Says HHS Drug Discount Rule Will Cost It Billions
• Judge Doubts Walmart's Preemptive Opioid Suit Can Prevail
• Fresenius Asks 3rd Circ. For Partial Redo Of Generics Opinion
• 10th Circ. Won't Revive J&J Unit Breast Implant Suit
• Alsup Slams UnitedHealthcare For 'Cherry-Picking' Facts
• Coronavirus Regulations: A State-By-State Week In Review
• Do Virus Response Liability Protections Cover Vaccinations?
• 10 Tips For Your Next Virtual Court Appearance
• 4 Firms Steer SPAC's $300M Israeli Medical Pot Co. Tie-Up
• PhRMA Latest To Sue HHS Over Pharmacy Discounts
• Ga. Board Can't Claim Immunity In SmileDirect Case, Feds Say
• J&J's Bid To Ax $15M Mesh Verdict Meets Skeptical NJ Court
• Feds Fire Back At Bid To Retry MiMedx Execs' Fraud Case
• Imerys Gets Nod On Updated Ch. 11 Plan Disclosures
• Companies Boost IPO Sizes As Another Blistering Week Starts
• Ex-Indivior Parent Withdraws $1.4B Claim Over Suboxone
• After Trump, Dem Probes May Turn To Companies
• Becton Investor Says Insiders Dumped Stock Ahead Of Recall
• 'Pharma Bro' Shkreli Can't Have FTC Prison Call Transcripts
• Eidos Therapeutics Investor Seeks Docs On BridgeBio Deal
• FTC Says Endo, Impax Cut 2nd Opana ER Pay-For-Delay Deal
• Drugmakers Must Face Warranty Claims In Valsartan MDL
• EpiPen Buyers Want Remote Testimony In Pricing MDL
• J&J, Bausch Beat Talc Products False Ad Claims
• Pa. County Says Medical Pot User Can't Guard Drug Offenders
• Merck Drops COVID-19 Vaccines After Disappointing Trials
• Don't Let Lies Infiltrate The Mediation Process
• Former Insys Execs Win 7th Virus-Induced Prison Delay
• High Court Won't Decide Arbitration Carveout Question
• Justices Reject Heart Monitor Patent Eligibility Case
• Judges On Race: Lack Of Data Deters Criminal Justice Reform
• Ret. Fed. Judges Call On Telecoms To Lower US-China IP Heat
• Raucous 2021 Awaits FCA Litigants After Low-Key Year
• Failure To Warn Claims Axed From Biomet Hip Implant Suit
• 1st Circ. Affirms Ex-Aveo CFO Committed Securities Fraud
• Polsinelli Says Clients' 'Slacking Off' Claims Are 'Meritless'
• US, Smith & Nephew Tell Justices PTAB Is Constitutional
• Diverse Atty Group Wins Lead Counsel In Elmiron MDL
• New Lead Plaintiff Seeks Cert. In Allergan Investor Action
• ITC To Probe Chinese Co. After Kan. AG Warns Of IP Theft
• Judge Won't DQ Class Rep In Suboxone 'Hopping' Suit
• BakerHostetler Picks Up IP Partner From Polsinelli
• NJ Employers Weigh Vaccine Rules Against Legal Liability
• DuPont, Others Commit $4B To 'Forever Chemical' Liabilities
• Cannabis Bill Roundup: A New Slate Of State Pot Reforms
• Insys Execs Safe In Prison With Biden Vaccine Plan, Feds Say
• 'Defective' Or 'Ordinary': PTAB Denials Suit Heats Up In Calif.
• 6th Circ. OKs Block On Chinese Heart-Device Sales In IP Fight
• Health Hires: Inspire Medical, Squire Patton Boggs
• Del. Books And Records Ruling Offers 4 Lessons For Cos.
• Taxation With Representation: Wilson, Faegre Drinker, Weil
• Breaking IP Barriers: Q&A With Finnegan's Mareesa Frederick
• Biotech Co. Vows Corporate Reforms To End Securities Suits
• Fed. Circ. Judge Calls High Court IP Decisions 'Inconsistent'
• Wash. Man Charged With Selling Untested COVID-19 Vaccine
• Bill To Recategorize Cannabis Kicks Off Federal Pot Reform
• Insys Founder To Pay NJ $5M In Opioid Bribery Settlement
• Brazil Conditionally Clears $825M Takeda Drug Divestment
• Ventilator Co. Says Rival's Poaching Hindered COVID-19 Work
• Prevail Investors Want Records From $1B Eli Lilly Deal
• Young Living's Oils Aren't Therapeutic, Buyers Claim
• Deals Rumor Mill: Joby Aero, Polynt-Reichhold, Starboard
• MLB Looks To Put Atty On Hook For Ex-Pitcher's Sanctions
• Faegre, Latham Drive $1.1B Boston Scientific-Preventice Deal
• Law Firms Should Note GCs' Growing Focus On Biz Strategies
• Biden To 'Fully Use' Defense Production Act In COVID-19 Plan
• Dentons Names Co-Head Of Its So. Cal. Venture Tech Group
• Biden DOJ May Ax Ban On 3rd-Party Donation Settlements
• Trump's Final Pardons Erase High-Profile Health Convictions
• Bard Mesh Expert's Bellwether Testimony 'Irrelevant': Patient
• Walmart Hit With Investor Suit Over DOJ Opioid Crisis Probe
• Real Estate Rumors: Yoya, Northeast Capital, Liberty Bank
• Latham-Led Medical Device Company Returns To IPO Market
• Takeda Pharmaceuticals Sued Over $1.8B Retirement Plan
• Mylan Wants Out Of Investor Suit Over FDA Inspections
• How Defense Production Act May Affect Vaccine Supply Chain
• Purdue Committees Get OK To Join Insurance Suits
• Queen's Gambit SPAC Among 6 That Raised $1.4B Via IPOs
• Illumina Rival Infringed DNA Sequencing IP, UK Court Rules
• 6 Changes The Legal Industry Should Prepare For
• DLA Piper, Cooley Craft Up To $510M Deal For Cardiva Medical
• Bayer Must Face Bulk Of Takeda's Hemophilia Drug IP Suit
• Pot Co. Says Oklahoma Residency Rule Unconstitutional
• PTAB Denies Bid To Review Eye Shot Patent, Citing ITC Case
• Lead Plaintiff In Endo Investors' Suit Slams Other Bids
• Hemp Biotech Biz Beats Investor Suit Over SEC Probe
• 4 Cos. Join IPO Pipeline Seeking To Raise $3.9B Total
• Drug Benefits Co. Valued At $1.1B In PE Deal Led By 3 Firms
• Genomic Testing Co. Preps $100M IPO Led By Cooley, Latham
• 11th Circ. Upholds $20M Punitive Award Against Philip Morris
• Purdue Insurer Says Committees Can't Bring Coverage Suits
• Arizona May Have Nudged US Law Firms Toward Future IPOs
• Coronavirus Regulations: A State-By-State Week In Review
• Mylan Can't Escape EpiPen Distributors' Antitrust Claims
• BPCIA Info Exchange Is Failing To Streamline Patent Litigation
• Biden Taps Trans Doctor For HHS Assistant Secretary
• 'Pharma Bro' Shkreli Again Denied Early Prison Release
• Shook Hardy Opens NYC Office With 2 Pharma Partners
• Iancu Resigns As USPTO Director, Urges Eligibility Reform
• Koch-Tied Org. Urges Miss. Justices To Keep Medical Pot Vote
• FCC Exempts Certain Pharma Calls From TCPA Rules
• Mallinckrodt OK'd To Pay Fees In Ch. 11 Despite Outcry
• Justices Reject Merck Bid To Revive $2.5B Patent Verdict
• Novo Joins Challenge To HHS Pharma Discount Opinion
• Miss. Businessman Gets 18 Years For $288M Tricare Fraud
• Fed. Circ. Sticks With Ruling In Bard's $68M Patent Fight
• Thermo Fisher Shells Out $876M For Viral Vector Maker
• Sanofi Prevails Over Mylan At Fed. Circ. On Jevtana Patent
• Ex-Insys Manager Frets Over 'Prison Parenting' In Delay Bid
• Real Estate Rumors: IQHQ, Beyond Meat, C-III Capital
• Imerys To Add Details Of $130M Talc Settlement In Ch. 11 Docs
• ICC Awards Mitsubishi $33M In Fight With Korean Pharma Co.
• 6 Priorities For Employment-Based Immigration Reform
• Pa. Judge Finds Catheter Makers Owe $1.25M To Inventor
• EU Rule Presents New Medical Device Compliance Hurdles
• Pa. Medical Pot Biz Says Ex-Employee Hacked Network
• Geneticist Tries To Dodge Cloning Suit From Polo Star
• Rite Aid Must Face Trial For Inflated Drug Price Claims
• Fruit Co. Must Destroy Juice In Deal To End FDA Suit
• UK Litigation Roundup: Here's What You Missed In London
• 4 Legal Industry Trends Litigation Financiers Are Watching
• Mallinckrodt Ch. 11 Talks Stalled Amid Fee Row, Judge Told
• DOJ's False Claims Haul Hits Decade Low At $2.2B
• 6th Circ. Won't Stop Ex-FDA Chief's Opioid MDL Testimony
• Biden Floats Stimulus Checks, Credits In $1.9T Of Virus Relief
• Diverse Atty Group Proposed As Lead Counsel In Elmiron MDL
• Medical Pot Producers Want NM Forced To Boost Plant Limit
• Patent Atty Slams Allergan Bid For Quick Appeal In FCA Case
• Lathrop Builds DC Presence With Ad Law Ace
• 3 Takeaways From Senate Insulin Pricing Probe
• Cannabis Firm Wants Pot Co.'s $5M Malpractice Claims Axed
• A Lawyer's Guide To Setting Well-Being Goals In 2021
• 4 Rulings That Will Shape Clickwrap Litigation In 2021
• Suit Dismissed Over Dr. Oz's 'Miracle' Diet Pills
• Lessons From 2020 Life Sciences Securities Class Actions
• Simpson-Steered PE Shop Amasses $10.2B Across 2 Funds
• 3 Firms Seek To Rep Biogen Investors In Securities Fraud Suit
• Whistleblowers Win $5.5M Atty Fees In Boston Scientific Case
• 9th. Circ. Won't Revive Suit Over Target Dietary Supplement
• Stem Cell Clinic Takes On FDA Regulations In 11th Circ.
• Drugmakers Sue HHS To Curtail Discounts To Pharmacies
• PTAB Mulls Analogous Prior Art In Sanofi, Mylan Injector Case
• Cole Schotz Nabs IP Atty From Thompson & Knight
• Keyword Searches To Improve Your Privilege Doc Review
• No Prison For Ex-Acclarent Execs In Off-Label Marketing Case
• United Cannabis' Ch. 11 Dismissed In Blow To Pot Sector
• Assignor Estoppel Case Could Fuel More Patent Attacks
• Justices Let FDA Require Abortion Pill Visits Amid Pandemic
• PBM Lobby Sues To Block Trump's 'Radical' Drug Rebate Rule
• Baxter Dodges Investor Suit Over Forex Accounting, For Now
• Consumers Can't Bring Out-Of-State Claims in Valsartan MDL
• Perrigo Urges US Judge Not To Delay $163.5M Tax Trial
• PTAB Judge Skeptical Allergan's Juvederm Patents Are Valid
• J&J Unhappy With Imerys' Ch. 11 Plan Disclosures
• Feds Want Jury Told Of Ex-Theranos CEO's 'Lavish Lifestyle'
• Pfizer Sues Over Generic For Arthritis Drug Xeljanz
• State AGs' 2020 Actions Offer Hints At 2021 Priorities
• 5 Blank-Check Cos. Raise $1.1B Amid Sizzling IPO Market
• US Trustee Says Mallinckrodt Fee Deals Still Defective
• The Benefits Of More Alternative Dispute Resolution At GAO
• Coronavirus Regulations: A State-By-State Week In Review
• Mass. Neuroscience Co. Minerva Hit With Stock-Drop Suit
• Ex-Acclarent Exec Rips Feds' Jail Request In Off-Label Case
• Food And Beverage Policy Trends To Monitor This Year
• ABA Approves Remote Practice, But Questions Remain
• Jones Day, Wachtell Lead $3.6B Deal For Medical Products Co.
• Impax Investors' Drug Price-Fixing Suit Revived By 9th Circ.
• Ex-FDA Chief Getting Biden Admin. Post, Opioid Atty Says
• Miss. Using 'Zombie Law' To Legalize Medical Pot, City Says
• Illumina Hit With Antitrust Suit Over Alleged Patent Fraud
• Humana Sues Teva Over Alleged Copay Fraud Scheme
• Trump Targets March-In Rights In Proposed Rule Change
• 3rd Circ. Revives Fresenius Generic Drug Suit
• Mylan, Pfizer Fight Remote Testimony In EpiPen Trial
• Name Brand Drug Cos. Ax Labeling Claims In Zantac MDL
• Ten IPOs Could Raise Nearly $5B As 2021 Gets Rolling
• Calif. Pot Agency Consolidation Planned For This Year
• Investors Sue Canadian Nanotech Co. Over COVID-19 Test
• Justices Turn Away 7 More IP Cases, Split Arthrex Arguments
• Greenberg Traurig Brings On Product Liability Atty In Miami
• Research Institute Settles Workers' FLSA Claims For $4.6M
• Calif. Agency Wins Pause Of $1B Destroyed Hemp Crop Suit
• Real Estate Rumors: Woodfield, Kaiser Permanente, Axonic
• GoodRx IPO Timed To Beat Amazon's Rival Launch, Suit Says
• Keys To Creating Standout Law Firm Thought Leadership
• Justices Won't Review Do-Overs Of Whistleblower FCA Cases
• Fed. Circ. Patent Decisions In 2020: An Empirical Review
• Weil, Goodwin Steer Sanofi's Up To $1.45B Bet On Drug Co.
• High Court Won't Nix Nat'l Class Ruling In Ill. Junk-Fax Case
• Becton Buyers Defend Revived Antitrust Suit
• Justices Nix 2nd Circ. Insider Trading Ruling After Bridgegate
• Bell Nunnally Adds IP Partner From Klemchuk
• Top 5 Criminal Justice Reforms Advocates Want Under Biden
• Judges On Race: The Power Of Discretion In Criminal Justice
• Ignore 'Scaremongering' On FCA Circuit Split, Justices Told
• Fed. Circ. Revives Fee Bid In Gardasil Vaccine Injury Case
• Drug. Co. Can't Keep Emails Under Wraps In Valsartan MDL
• DuPont Dodges Ex-Worker's Pregnancy Bias Suit
• Kilpatrick Nabs Ex-MoFo IP Life Sciences Litigator
• DOL Says 'No Checklist' For Ministerial Exception To FLSA
• Pomerantz Asks To Take Lead Of Endo Investors' Suit
• Justices To Review Assignor Estoppel In Patent Cases
• 4 Things Garland Could Do For Marijuana Reform As AG
• Shkreli Can't Pause Suit Pending Prison Release, Judge Says
• Ex-Manager Says 'Stale' Ecolab Docs Aren't Trade Secrets
• Imerys Insurers Say Not Enough Info On $130M Cyprus Deal
• 4 Firms Lead Cancer-Centric Biotechs In IPOs Totaling $459M
• 5 Major Drug And Medical Device Developments In 2020
• Taxation With Representation: Wachtell, Cravath, Skadden
• Convicted Insys Founder Wants Vaccine First, Prison Later
• Cooley, Skadden Rep Cancer Biotech's $1.7B Go-Public Deal
• 5 Attorney Business Development Tips For The New Year
• UK Litigation Roundup: Here's What You Missed In London
• Life Sciences Cos. Increasingly Turn To Arbitration
• Unilever Sued Over Hair Loss, Formaldehyde In Its Shampoos
• Fed. Circ. Judge Suggests Columbia's DNA IP Was Known
• Butler Snow Hires Scott Douglass McConnico Trial Pro
• DOJ Urges Prison Time For Former Acclarent Execs
• HDI Global Shakes Pharma Co.'s Advertising Coverage Row
• Swedish Biotech Oasmia Settles Investor Claims For $2.4M
• NY To Push Back On Efforts To Split Landmark Opioid Trial
• FEMA Finalizes Rule Prioritizing Federal Medical Contracts
• How 2020 Changed Product Liability — And What's Next
• 10 Ways Antitrust Scrutiny Is Heating Up In 2021
• After Lull In Biosimilar IP Litigation, 2021 Could Bring Influx
• Insurers Urge Court To Preserve Cancer Drug Antitrust Suit
• Minimizing Disruption To Clients During Law Firm IT Upgrades
• DOJ Misled Court About Planned Opioid Suit, Walmart Says
• Medical Marijuana Investor Suit Punted Back To Trial Court
• DNA IP Ruling Creates 'Serious Ethical' Issues, Justices Told
• Trump Signs Bill To Organize Drug Patent Listings
• Trump Signs Bill Allowing FDA Seizure Of Counterfeits
• Fed. Circ. Won't Let Bull Semen Co. Appeal Moot PTAB Loss
• Fed. Circ. Won't Revive Axed Horizon Pain Drug Patents
• White House Slams 'Opportunistic' COVID-19 Scammers
• US, EU Call Out India During WTO's Trade Review
• Moderna COVID-19 Vaccine Gets OK'd In EU
• W.Va. Opioid Distributor Bellwether Trial Set For May
• More Than 20 Firms Guided The Top Real Estate Deals Of 2020
• 4th Circ. Undoes $1.25M Verdict In Pradaxa Suit
• Gov't Pandemic Response Will Boost Life Sciences In 2021
• FCA Whistleblowers Are More Important Than Ever Before
• Allergan Says Federal Law Preempts Breast Implant Claims
• 10 Patent Prosecution, Litigation Practice Trends From 2020
• Real Estate Rumors: Ross, Magellan, East West Development
• 5th Circ. Told To Undo Sanofi's Win In Chemo Hair Loss Row
• Pot Legalization Still Faces Hurdles After Senate Flip
• Feds Want In On Allergan Collusion Suit Amid Criminal Probe
• Hatch-Waxman Venue Issue Still Live After Fed. Circ. Ruling
• Tips For Drafting Effective Amicus Briefs
• 5 Firms Drive $6.5B Sale Of Walgreens' Health Care Division
• Mylan Urges Fed. Circ. To Keep Hatch-Waxman Venue Limits
• 8th Circ. Affirms Injunction Blocking 2 Ark. Abortion Laws
• Ga. Board Pushes 11th Circ. For Immunity From SmileDirect
• NY Legislators Refile Bill To Legalize Cannabis
• Biomet Strikes Back Against $3.5M Hip Implant Verdict
• Investors Say NJ Firm Snuck Off With $2.6M In Pot Profits
• Split 11th Circ. Upholds Magellan Health Noncompete
• Merck, Glenmark Fight Zetia Class Cert. At 4th Circ.
• Coronavirus Regulations: A State-By-State Week In Review
• 5 Trends That Will Influence E-Discovery In 2021
• Virus Prompts Delay Of Del. Trial Over Testosterone Drug
• Health Care Co. Appeals Contract Terminations To 6th Circ.
• John Wiley Buys Open Access Publisher For $298M
• DC Judge Calls Teva's Bid To Reclassify Drug Anticompetitive
• Allergan Seeks Quick Appeal After Failing To Nix FCA Suit
• Gilead 'Rewriting' History To Save $2.5B IP Win, Justices Told
• Inventors Urge Justices To Restore Patent Balance In Arthrex
• Special Masters Tapped In Valsartan Contamination MDL
• DOJ Attys Dish On Indivior Opioid Case As Sentencing Wraps
• PhRMA Denied Early Win In Drug Pricing Law Case
• B. Braun Medical Ex-Workers Fight To Save 401(k) Fee Dispute
• Skadden-Led Dental Products Co. Buys Aligner Maker For $1B
• DOJ Backs AbbVie At 7th Circ. In 'Patent Thicket' Case
• Overlooked Patent Cases: Willful Infringement Developments
• Pair Of Cancer-Focused Biotechs Launch IPOs Totaling $300M
• Prep For Increased Pay Equity Enforcement In Gov't Contracts
• Zantac Generics MDL Labeling Claims Axed As Preempted
• Calif. Federal Forum Clause Rulings Are Good News For Cos.
• How Relationship Partners Can Draft Winning RFP Responses
• Law Firm Merger Predictions For 2021
• Securities Litigation Trends That Will Matter Most In 2021
• Antitrust Conduct Cases To Watch In 2021
• 4 Key Areas As Biden Sets New Health Policy Path In 2021
• 2020 ERISA Litigation Trends Hint At What's Ahead This Year
• Patent Policy To Watch In 2021
• Epic Litigation Landscape Awaits Health, Life Sci Attys In 2021
• Patent Cases To Watch In 2021
• 2021 Trials To Watch As Litigants Return To Court — Hopefully
• Cannabis Policy Items To Watch In 2021
• Product Liability Cases To Watch In 2021
• Lessons For 2021 From Fed. Circ. Post-Grant Review Cases
• ERISA Arbitration, New Legal Theories To Be Tested In 2021
• The Biggest UK IP Cases To Watch In 2021
• California Cases To Watch In 2021
• Top Gov't Contracts Cases To Watch In 2021
• California Legislation And Regulation To Watch In 2021
• Patent Litigation Trends To Watch In 2021